Sangamo BioSciences | SGMO - Gross Profit On Sales


Sangamo BioSciences reported -2.39M in Gross Profit on Sales for its fiscal quarter ending in June of 2024.





Gross Profit On Sales Change Date
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Bayer EUR 6.94B 1.58B Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Cipla INR 39.1B 2.54B Mar/2026
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 352K 63.44M Mar/2026
CSL USD 4.46B 2.71B Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
GlaxoSmithKline GBP 5.75B 429M Mar/2026
Grifols EUR 766.49M 39.74M Dec/2024
Ionis Pharmaceuticals USD 243M 48M Mar/2026
J&J USD 18.55B 1.31B Jun/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Merck USD 10.85B 2.57B Dec/2025
Novartis USD 10.07B 184M Mar/2026
Omeros USD -33.16M 18.52M Jun/2024
Pfizer USD 11.04B 1.24B Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026